GlassScriptPhysician profile
Chinelo Madubom
NPI 1568844322
$3,774.52
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $270 · 2021: $720 · 2022: $1,014 · 2023: $910 · 2024: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.54 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $500.76 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.56 | 2020-2024 | Jardiance, Synjardy |
| Novo Nordisk INC | $387.74 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $362.10 | 2020-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $247.77 | 2021-2024 | |
| Abbvie INC. | $214.22 | 2021-2024 | |
| Glaxosmithkline, LLC. | $168.64 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.27 | 2020-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $151.25 | 2022-2024 | Veozah, Myrbetriq |
| Renalytix Ai, INC. | $137.34 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Amgen INC. | $128.68 | 2020-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $116.98 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $108.54 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $106.39 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $81.02 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $49.58 | 2022-2023 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $48.18 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $45.06 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $44.26 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $34.87 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.43 | 2022 | |
| Merck Sharp & Dohme LLC | $27.02 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $24.68 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $23.00 | 2021 | |
| Eisai INC. | $22.50 | 2021 | |
| Inspire Medical Systems, INC. | $21.86 | 2023 | Inspire |
| Janssen Pharmaceuticals, INC | $20.73 | 2021 | |
| Sanofi Pasteur INC. | $19.51 | 2023 | |
| Phathom Pharmaceuticals, INC. | $19.22 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $16.76 | 2021 | |
| Currax Pharmaceuticals LLC | $15.45 | 2023 | Contrave, Nexletol, Nexlizet |
| Azurity Pharmaceuticals, INC. | $15.02 | 2023 | Edarbi |
| Myocardial Solutions, INC. | $14.80 | 2021 | |
| Hikma Pharmaceuticals USA | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chinelo Madubom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.